Illumina (ILMN) Inks Deal To Develop Distributable Test Kits
Zacks Investment Research | Sep 25, 2019 08:44AM ET
Illumina, Inc. (NASDAQ:ILMN) recently signed a partnership deal with Adaptive Biotechnologies Corporation (NASDAQ:ADPT) , a commercial stage biotechnology company. The deal will enable clinicians to carry out clinical immunodiagnostic testing that can be conducted in local laboratories. Moreover, the collaboration will boost Illumina’s strong in-vitro diagnostic (IVD) portfolio.
Adaptive Biotechnologies is striving to decode the genetics of the adaptive immune system into clinical products to diagnose and treat diseases.
Also, the collaboration will enable Illumina to improve its foothold in the global IVD market.
Significance of the Collaboration
Per the terms of the partnership, Illumina will develop customized software to support the use of the kits on NextSeq instruments. Also, the company will provide regulatory and related support related to its components as well as the software. It will exclusively license the software to Adaptive Biotechnologies. These test kits will enable hospitals and healthcare providers to use Adaptive Biotechnologies’ clonoSEQ and immunoSEQ Dx assays in their respective laboratories across the United States.
Through this collaboration, Illumina aims to reach out to more people to ensure better access to healthcare. Also, it plans to make clonoSEQ more accessible to patients and include the healthcare providers into the growing genomics ecosystem. The partnership will facilitate Illumina to expand access to genomic-based testing and improve patient outcomes.
A Peek Into Illumina’s IVD Portfolio
Illumina’s next-generation sequencing (NGS) technology offers broader view of the human genome. This helps clinicians to determine and apply relevant genomic information to human health. The company is focused on improving health by tapping the huge potential of the human genome.
Illumina is currently aiming to expand the clinical applications of its NGS platform through products like the MiSeqDx System and the TruSeq Custom Amplicon Kit Dx.
Recent Developments
The company announced the launch of VeriSeq NIPT Solution v2, a CE-IVD, NGS-based approach to noninvasive prenatal testing (NIPT) in June 2019. It is an automated comprehensive solution that enables laboratories to look for a broader array of chromosomal and sub-chromosomal conditions associated with birth defects as well as adverse pregnancy outcomes than the standard NIPT menu.
Get The News You Want
Industry Prospects
Per a report by Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.